RecruitingNCT07039552

Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands

Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands With BRCA1/2 Germline Mutations


Sponsor

Peking University Third Hospital

Enrollment

10,000 participants

Start Date

Jan 1, 2016

Study Type

OBSERVATIONAL

Conditions

Summary

Ovarian cancer is the gynecological malignancy with the highest fatality rate, seriously threatening the life and health of women. One of the main reasons for its high fatality rate is that approximately 70% of patients are diagnosed at an advanced stage. Fortunately, about 1/5 of ovarian cancers are associated with genetic factors, providing us with an opportunity to screen high-risk populations and thereby prevent and diagnose the disease at an early stage and reduce the disease burden. Currently, research related to hereditary ovarian cancer in China is still very scarce, and clinical practice relies on data from foreign studies. However, hereditary tumors have distinct regional and ethnic characteristics, making it urgent to conduct clinical research based on the Chinese population to guide clinical practice in China. Current research suggests that approximately 50% - 60% of hereditary ovarian cancers are closely related to the BRCA1/2 genes. Therefore, accurately assessing the risk of ovarian cancer in BRCA1/2 germline mutation carriers is of great significance for the prevention and treatment of hereditary ovarian cancer.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study builds and tests a model to predict ovarian cancer risk for close family members of women diagnosed with ovarian cancer, especially those who carry BRCA1 or BRCA2 genetic mutations that significantly raise cancer risk. **You may be eligible if...** - You have been diagnosed with an ovarian malignant tumor - You have tested positive for a harmful BRCA1 or BRCA2 genetic mutation - You have close family members who may also be at risk - You are willing to provide genetic and medical data **You may NOT be eligible if...** - You do not have a confirmed pathological diagnosis of ovarian cancer - You do not carry a BRCA1/2 mutation - You are unwilling to share relevant family history and genetic information Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURErisk-reducing salpingo-oophorectomy (RRSO)

The proportion of BRCA1/2 germline mutation carriers in the high-risk population of ovarian cancer who undergo risk-reducing salpingo-oophorectomy (RRSO). RRSO refers to the preventive surgical removal of both fallopian tubes and ovaries to reduce the risk of ovarian cancer, fallopian tube cancer, and peritoneal cancer.


Locations(1)

Peking University Third Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07039552


Related Trials